Why the study?
Does dabigatran provide effective VTE prophylaxis following hip and knee replacement?
Does dabigatran provide effective VTE prophylaxis following hip and knee replacement?
This review discusses the clinical data on the efficacy and adverse effects of dabigatran for VTE prophylaxis after hip and knee replacement.
Answers are grounded in this paper and cite their sources.
May guide individualized VTE prophylaxis choices post-arthroplasty; leaves open need for updated RCTs.
Dabigatran (Pradaxa) is a new orally active antithrombotic agent licensed for VTE prophylaxis following hip and knee replacement. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Professor Simon Frostick comments on its place in therapy.
No takes yet. Share an insight, caveat, or question.
Chaplin et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: